Limits...
Early transient radiation-induced brachial plexopathy in locally advanced head and neck cancer.

Metcalfe E, Etiz D - Contemp Oncol (Pozn) (2016)

Bottom Line: Maximum dose to the BP was ≥ 70 Gy only in 2 nasopharyngeal cancer patients.Two (7%) early transient RIBP were reported at 7(th) and 8(th) month after RT under maximum 67.17 and 55.37 Gy, and mean 52.95 and 38.60 Gy RT doses.Two (7%) early RIBP were seen in the patient group, although brachial plexus maximum doses were ≥ 66 Gy in 75% of patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Eskisehir Osmangazi University School of Medicine, Turkey.

ABSTRACT

Aim of the study: Early transient brachial plexopathy following radiotherapy (RT) in patients with head and neck cancer may be underreported and associated with a dose-response. Our purpose was to determine the incidence of early transient radiation-ınduced brachial plexopathy (RIBP) in patients receiving primary RT (± chemotherapy) for locally advanced head and neck cancer (HNC).

Material and methods: Twenty-seven locally advanced HNC patients who have no finding of brachial plexopathy at the diagnosis were evaluated 3 times by a specifically developed 13-item questionnaire for determining early transient RIBP. The 54 brachial plexus in 27 patients were delineated and dose volume histograms were calculated.

Results: Median follow-up period was 28 (range: 15-40) months. The mean BP volume was 7.9 ±3.6 cm(3), and the mean and maximum doses to the BP were 45.3 (range: 32.3-59.3) Gy, and 59.4 (range: 41.4-70.3) Gy, respectively. Maximum dose to the BP was ≥ 70 Gy only in 2 nasopharyngeal cancer patients. Two (7%) early transient RIBP were reported at 7(th) and 8(th) month after RT under maximum 67.17 and 55.37 Gy, and mean 52.95 and 38.60 Gy RT doses.

Conclusions: Two (7%) early RIBP were seen in the patient group, although brachial plexus maximum doses were ≥ 66 Gy in 75% of patients.

No MeSH data available.


Related in: MedlinePlus

A,B,C, and D passing through level of C5, C6, C7, and T1, respectively, shows contouring the brachial plexus (BP) (patient no. 4)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4829741&req=5

Figure 0001: A,B,C, and D passing through level of C5, C6, C7, and T1, respectively, shows contouring the brachial plexus (BP) (patient no. 4)

Mentions: Tumor and OAR volumes were contoured in accordance with the RTOG atlas for head and neck contouring and the relevant literature (Fig. 1) [3–6].


Early transient radiation-induced brachial plexopathy in locally advanced head and neck cancer.

Metcalfe E, Etiz D - Contemp Oncol (Pozn) (2016)

A,B,C, and D passing through level of C5, C6, C7, and T1, respectively, shows contouring the brachial plexus (BP) (patient no. 4)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4829741&req=5

Figure 0001: A,B,C, and D passing through level of C5, C6, C7, and T1, respectively, shows contouring the brachial plexus (BP) (patient no. 4)
Mentions: Tumor and OAR volumes were contoured in accordance with the RTOG atlas for head and neck contouring and the relevant literature (Fig. 1) [3–6].

Bottom Line: Maximum dose to the BP was ≥ 70 Gy only in 2 nasopharyngeal cancer patients.Two (7%) early transient RIBP were reported at 7(th) and 8(th) month after RT under maximum 67.17 and 55.37 Gy, and mean 52.95 and 38.60 Gy RT doses.Two (7%) early RIBP were seen in the patient group, although brachial plexus maximum doses were ≥ 66 Gy in 75% of patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Eskisehir Osmangazi University School of Medicine, Turkey.

ABSTRACT

Aim of the study: Early transient brachial plexopathy following radiotherapy (RT) in patients with head and neck cancer may be underreported and associated with a dose-response. Our purpose was to determine the incidence of early transient radiation-ınduced brachial plexopathy (RIBP) in patients receiving primary RT (± chemotherapy) for locally advanced head and neck cancer (HNC).

Material and methods: Twenty-seven locally advanced HNC patients who have no finding of brachial plexopathy at the diagnosis were evaluated 3 times by a specifically developed 13-item questionnaire for determining early transient RIBP. The 54 brachial plexus in 27 patients were delineated and dose volume histograms were calculated.

Results: Median follow-up period was 28 (range: 15-40) months. The mean BP volume was 7.9 ±3.6 cm(3), and the mean and maximum doses to the BP were 45.3 (range: 32.3-59.3) Gy, and 59.4 (range: 41.4-70.3) Gy, respectively. Maximum dose to the BP was ≥ 70 Gy only in 2 nasopharyngeal cancer patients. Two (7%) early transient RIBP were reported at 7(th) and 8(th) month after RT under maximum 67.17 and 55.37 Gy, and mean 52.95 and 38.60 Gy RT doses.

Conclusions: Two (7%) early RIBP were seen in the patient group, although brachial plexus maximum doses were ≥ 66 Gy in 75% of patients.

No MeSH data available.


Related in: MedlinePlus